LIPOMATRIX TRIGLYCERIDE-FILLED BREAST IMPLANT U.S. CLINICALS TO BEGIN
This article was originally published in The Gray Sheet
Executive Summary
LIPOMATRIX TRIGLYCERIDE-FILLED BREAST IMPLANT U.S. CLINICALS TO BEGIN in September under an investigational device exemption approved by FDA July 15. LipoMatrix will be seeking a maximum of 50 patients "with older, but problematic implants" to take part in a five-center pilot trial studying the company's Trilucent breast implant as a replacement device.